Vanguard Capital Management
CTOR

Vanguard Capital Management’s Citius Oncology CTOR Stock Holding History

Vanguard Capital Management’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Buy
546,325
+11,501
+2% +$9.16K ﹤0.01% 3766
2026
Q1 		$332K Buy
+534,824
New +$537K ﹤0.01% 3732

Other funds holding CTOR

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Vanguard Capital Management's CTOR Position: Q2 2026 in Review

Vanguard Capital Management increased its Citius Oncology (CTOR) stake by 2.2% in Q2 2026, buying an estimated $9.16K and bringing the position to 546,325 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #3766.

Vanguard Capital Management first reported a position in CTOR in Q1 2026 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold CTOR as of Q2 2026.

  • Vanguard Capital Management held 546,325 shares of Citius Oncology worth $355K as of Q2 2026.
  • Vanguard Capital Management bought 11,501 Citius Oncology shares in Q2 2026, an estimated $9.16K.
  • Citius Oncology made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3766 holding.
  • Vanguard Capital Management first reported a position in Citius Oncology in Q1 2026 and has held it in 2 quarters since.
  • 20 funds tracked by Wall St. Rank held Citius Oncology as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.